Loading the company…
Loading the company…
In the last ten years FDA made 4 decisions for Kerecis (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2025 (1). The latest was on 2025-07-16.
| Family | Decisions on record |
|---|---|
| Skin substitutes & wound grafts | 5 |
In 2025, Kerecis reported engagement with 9,642 surgeons and other clinicians in the states MedaRep covers, worth $3.7M in consulting, speaking, meals and travel for its device products, the most in New York ($571K to 589). Royalties are left out.
| MARIGEN WOUND DRESSING |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Kerecis.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($571K, 589 engaged), Illinois ($470K, 513 engaged), Florida ($388K, 1,045 engaged), Texas ($378K, 879 engaged), Georgia ($215K, 283 engaged).